Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemia.
BACKGROUND
We previously reported that allanxanthone C and macluraxanthone, two xanthones purified from Guttiferae trees, display in vitro antiproliferative and proapoptotic activities in leukemic cells from chronic lymphocytic leukemia (CLL) and leukemia B cell lines.


RESULTS
Here, we investigated the in vivo therapeutic effects of the two xanthones in a xenograft murine model of human CLL, developed by engrafting CD5-transfected chronic leukemia B cells into SCID mice. Treatment of the animals with five daily injections of either allanxanthone C or macluraxanthone resulted in a significant prolongation of their survival as compared to control animals injected with the solvent alone (p = 0.0006 and p = 0.0141, respectively). The same treatment of mice which were not xenografted induced no mortality.


CONCLUSIONS
These data show for the first time the in vivo antileukemic activities of two plant-derived xanthones, and confirm their potential interest for CLL therapy.
EA 2216, Université de Bretagne, Brest, France.
Séverine
S
Loisel
Karine
K
Le Ster
Michèle
M
Meyer
Christian
C
Berthou
Pierre
P
Youinou
Jean-Pierre
JP
Kolb
Christian
C
Billard
D000818:Animals; D045744:Cell Line, Tumor; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D051379:Mice; D016513:Mice, SCID; D044004:Xanthones / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
D044004:Xanthones; C508597:allanxanthone C